Hengrui Medicine Reports H1 Revenue of 15.456 Billion Yuan with Net Profit Up Just 0.34%
Nashnova编辑部
Hengrui Medicine (恒瑞医药) reported H1 revenue of RMB 15.456 billion, down 1.94% year-on-year, with net profit of RMB 4.465 billion — up a mere 0.34%. The company simultaneously announced a RMB 1–2 billion share buyback to shore up the stock.
How good — or bad — is this scorecard?
H1 revenue came in at RMB 15.456 billion, down 1.94% year-on-year — a mild top-line contraction.
Net profit attributable to shareholders reached RMB 4.465 billion, up only 0.34% — effectively flat.
This means → revenue shrank but profit didn't follow it down, suggesting the company tightened costs. Still, growth momentum is clearly weak and profitability is under pressure.
Revenue fell — so why did profit still inch higher?
Revenue dropped by roughly RMB 300 million year-on-year, yet profit edged up rather than declining in tandem.
In plain terms = the company earned slightly less but cut spending by even more, so the bottom line barely held.
This reflects Hengrui's active cost discipline during a period of top-line pressure, defending the profit floor.
Can the buyback support the share price?
Hengrui announced a planned buyback of RMB 1–2 billion in shares, capped at RMB 81.78 per share.
This means → management believes the stock is undervalued and is willing to put real money behind that conviction.
The buyback is modest relative to the company's market cap, however; its actual impact on the share price depends on execution pace and broader market sentiment.
Content is for reference only, not financial advice.